CNS Pharmaceuticals (CNSP) Non-Current Assets (2018 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly Non-Current Assets came in at $520665.0 in Q4 2025, up 1126.97% YoY from $42435.0 in Q4 2024, and up 9.03% on a QoQ basis from $477523.0 in Q3 2025.
CNS Pharmaceuticals (CNSP) Non-Current Assets (2018 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 8 years of Non-Current Assets data on file, last reported at $520665.0 in Q4 2025.
- Quarterly Non-Current Assets rose 1126.97% year-over-year to $520665.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $520665.0 (up 1126.97% YoY) and the FY2025 annual result came in at $520665.0, up 1126.97% from the prior year.
- Non-Current Assets rose to $520665.0 in Q4 2025, from $477523.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $1.3 million in Q4 2021 to a low of $21175.0 in Q3 2024.
- A 5-year average of $450054.8 and a median of $364149.0 in 2021 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets tumbled 92.05% — and 2025, when it soared 2155.13%.
- Tracing CNSP's Non-Current Assets over 5 years: stood at $1.3 million in 2021, then slumped by 61.84% to $488470.0 in 2022, then plunged by 77.55% to $109683.0 in 2023, then slumped by 61.31% to $42435.0 in 2024, then soared by 1126.97% to $520665.0 in 2025.
- The last three Non-Current Assets figures came in at $520665.0 (Q4 2025), $477523.0 (Q3 2025), and $370055.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | CNS Pharmaceuticals | 2.65 Mn | -4.55 Mn | - | 520,665.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 520,665.00 |
| Sep 30, 2025 | 477,523.00 |
| Jun 30, 2025 | 370,055.00 |
| Mar 31, 2025 | 27,289.00 |
| Dec 31, 2024 | 42,435.00 |
| Sep 30, 2024 | 21,175.00 |
| Jun 30, 2024 | 323,873.00 |
| Mar 31, 2024 | 59,601.00 |
| Dec 31, 2023 | 109,683.00 |
| Sep 30, 2023 | 266,201.00 |
| Jun 30, 2023 | 380,578.00 |
| Mar 31, 2023 | 442,516.00 |
| Dec 31, 2022 | 488,470.00 |
| Sep 30, 2022 | 937,558.00 |
| Jun 30, 2022 | 1.05 Mn |
| Mar 31, 2022 | 1.14 Mn |
| Dec 31, 2021 | 1.28 Mn |
| Sep 30, 2021 | 351,664.00 |
| Jun 30, 2021 | 355,033.00 |
| Mar 31, 2021 | 358,243.00 |